Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5846267 | Toxicology and Applied Pharmacology | 2014 | 9 Pages |
Abstract
The relevance of P-glycoprotein (P-gp) for irinotecan chronopharmacology was investigated in female B6D2F1 mice. A three-fold 24 h change in the mRNA expression of Abcb1b was demonstrated in ileum mucosa, with a maximum at Zeitgeber Time (ZT) 15 (p < 0.001). No rhythm was found for abcb1a in ileum mucosa, or for Abcb1a/b in Glasgow osteosarcoma (GOS), a mouse tumor cell line moderately sensitive to irinotecan. Non-tumor-bearing mice received irinotecan (50 mg/kg/day i.v. Ã 4 days) as a single agent or combined with P-gp inhibitor PSC833 (6.25 mg/kg/day i.p. Ã 4 days) at ZT3 or ZT15, respectively corresponding to the worst or the best irinotecan tolerability. Endpoints involved survival, body weight change and hematologic toxicity. Antitumor efficacy was studied in GOS-bearing mice receiving irinotecan (25, 30 or 40 mg/kg/day Ã 4 days) and +/â PSC833 at ZT3 or ZT15, with survival, body weight change, and tumor growth inhibition as endpoints. Non-tumor bearing mice lost an average of 17% or 9% of their body weight according to irinotecan administration at ZT3 or ZT15 respectively (p < 0.001). Dosing at ZT15 rather than ZT3 reduced mean leucopenia (9% vs 53%; p < 0.001). PSC833 aggravated irinotecan lethal toxicity from 4 to ~ 60%. In tumor-bearing mice, body weight loss was ~ halved in the mice on irinotecan or irinotecan-PSC833 combination at ZT15 as compared to ZT3 (p < 0.001). PSC833-irinotecan at ZT15 increased tumor inhibition by ~ 40% as compared to irinotecan only at ZT15. In conclusion, P-gp was an important determinant of the circadian balance between toxicity and efficacy of irinotecan.
Related Topics
Life Sciences
Environmental Science
Health, Toxicology and Mutagenesis
Authors
Elisabeth Filipski, Elodie Berland, Narin Ozturk, Catherine Guettier, Gijsbertus T.J. van der Horst, Francis Lévi, Alper Okyar,